Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409432 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
A Phase 2 study, sponsored by John Reneau.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03409432 is a Phase 2 study that has completed, run by John Reneau. The registered enrollment target is 26 participants.
The verdict
NCT03409432, a Phase 2 study, has completed, sponsored by John Reneau.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase II trial studies how well brentuximab vedotin and lenalidomide work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Lenalidomide
- DRUG Brentuximab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-03-16 |
| Est. Completion | 2025-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03409432
The ClinicalTrials.gov registry entry for NCT03409432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Reneau, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03409432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03409432 about?
NCT03409432 is a clinical study titled "Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma". This phase II trial studies how well brentuximab vedotin and lenalidomide work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spr...
What is the current status of trial NCT03409432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2018-03-16. Estimated completion is 2025-07-16.
What interventions are being tested in trial NCT03409432?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Lenalidomide (DRUG), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT03409432?
This trial is sponsored by John Reneau, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.